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Background: Drug resistance surveillance is crucial for tuberculosis (TB) control. Therefore, 
our goal was to determine the prevalence of second-line anti-TB drug resistance among diverse 
primary drug-resistant Mycobacterium tuberculosis complex (MTBC) isolates in Ghana. 
Materials and methods: One hundred and seventeen MTBC isolates with varying first-line 
drug resistance were analyzed. Additional resistance to second-line anti-TB drugs (streptomycin 
[STR], amikacin [AMK] and moxifloxacin [MOX]) was profiled using the Etest and GenoType 
MTBDRsl version 2.0. Genes associated with resistance to AMK and MOX (gyrA, gyrB, eis, 
rrs, tap, whiB7 and tlyA) were then analyzed for mutation.
Results: Thirty-seven (31.9%) isolates had minimum inhibitory concentration (MIC) values 
≥2 µg/mL against STR while 12 (10.3%) isolates had MIC values ≥1 µg/mL for AMK. Only 
one multidrug-resistant (MDR) isolate (Isolate ID: TB/Nm 919) had an MIC value of ≥0.125 
µg/mL for MOX (MIC = 3 µg/mL). This isolate also had the highest MIC value for AMK 
(MIC = 16 µg/mL) and was confirmed as resistant to AMK and MOX by the line probe assay 
GenoType MTBDRsl version 2.0. Mutations associated with the resistance were: gyrA (G88C) 
and rrs (A514C and A1401G).
Conclusion: Our findings suggest the need to include routine second-line anti-TB drug sus-
ceptibility testing of MDR/rifampicin-resistant isolates in our diagnostic algorithm. 
Keywords: tuberculosis, drug resistance, diagnosis, Ghana, XDR
Introduction
Tuberculosis (TB), which has killed more humans than any infectious disease, remains 
a global health challenge. Over 10 million people got sick and 1.4 million individuals 
died of TB in 2015, with most of the affected individuals living in resource-constrained 
countries.1 The burden of TB is worsened by the emergence of strains that are resistant 
to standard TB drugs, threatening to make a treatable disease untreatable. Individuals 
infected with resistant strains have to take anti-TB drugs for longer periods and cure 
rates are lower compared to infection with susceptible strains.1,2 
The standard World Health Organization (WHO)-approved treatment greatly relies 
on the use of two potent drugs, that is, isoniazid (INH) and rifampicin (RIF).3,4 TB 
strains that are resistant to these two drugs are classified as multidrug-resistant TB 
(MDR-TB). More severe forms of TB drug resistance are pre-extensively drug-resistant 
TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB).1,5–9 XDR-TB has 
been reported in 117 countries worldwide with treatment success of 28%.1 
The first key intervention for controlling drug resistance is early detection, for 
appropriate treatment.1,2 The increased use of new and rapid diagnostic tools such as 
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Xpert MTB/RIF and line probe assays (GenoType MTB-
DRplus and GenoType MTBDRsl) is ensuring that signifi-
cantly more TB patients are correctly diagnosed on time. 
The National Tuberculosis Control Programme (NTP), 
Ghana, is now rolling out some of these rapid diagnostic 
methods to support case management: GenoType MTB-
DRplus for rapid detection of MDR-TB, which has been 
evaluated for use in Ghana,10 Xpert MTB/RIF for RIF resis-
tance and GenoType MTBDRsl for detection of XDR-TB. 
There is limited data on drug resistance in Ghana, espe-
cially, resistance to second-line anti-TB drugs. The study 
objective was to determine the prevalence of second-line 
anti-TB drug resistance in Ghana.
Materials and methods
ethics statement
The procedure for sample collection, diagnosis and treatment 
was done in accordance with NTP guidelines,11 and ethical 
clearance for this study was obtained from the Noguchi 
Memorial Institute for Medical Research Institutional Review 
Board (FWA 00001824, IRB 00001276). 
Mycobacterial isolates
Isolates analyzed in this study were obtained from pulmo-
nary patients attending various health facilities in the Accra 
Metro and the East Mamprusi District in the Greater-Accra 
and Northern regions of Ghana, respectively. The isolates 
included new TB cases, which form part of a prospective 
molecular epidemiology study, and those obtained from 
difficult-to-treat cases attending the Department of Chest 
Diseases, Korle-Bu Teaching Hospital. The drug suscepti-
bility pattern of the isolates to the first-line anti-TB drugs 
was determined using the proportion method and GenoType 
MTBDRplus. In total, 71 (60.7%) MDR-TB, 33 (28.2%) 
INH monoresistant TB and 13 (11.1%) RIF monoresistant 
TB isolates were analyzed. 
Isolation of genomic Dna
A loop full of mycobacterial isolate growing at the log phase 
was suspended in sterile distilled water and inactivated 
by heat killing at 95oC for 1 h. Genomic DNA was then 
extracted using the cetyl-trimethyl-ammonium bromide 
(CTAB) extraction method developed by Doyle and Doyle 
with modifications by Käser et al.12,13 Briefly, the initial cell 
lysis was done by resuspending the pellets in lysis buffer 
containing lysozyme and then incubating overnight at 37°C. 
Then, 20% sodium dodecyl sulphate (SDS) and 20 mg/mL 
proteinase K (PK) were added, respectively and mixed  gently. 
The cell debris was removed by adding sodium chloride 
(NaCl) and prewarmed using CTAB and incubated at 65oC. 
After incubation with chloroform-isoamyl alcohol at a 24:1 
ratio to remove protein debris, the DNA in the aqueous phase 
was purified with ice-cold isopropanol. The DNA was dried 
and resuspended in 1X Tris-EDTA buffer.12,13
Anti-TB drug susceptibility testing
The Etest (bioMérieux, Marcy-l’Étoil, France) method, which 
determines the minimum inhibitory concentration (MIC), 
was used to screen 117 resistant isolates against amikacin 
(AMK), streptomycin (STR) and moxifloxacin (MOX). 
McFarland Standard 4 bacteria suspension, corresponding 
to an approximate cell density of 12.0 ×108 CFU/mL,14 was 
prepared using Middlebrook 7H9 with 10% Tween 80 (7H9G-
Tween) and inoculated on Middlebrook 7H11 agar plates 
with oleic albumin dextrose catalase media supplement. 
Etest strips of distinct drugs were placed aseptically on the 
plates using forceps and incubated at 37oC.15,16 The MIC was 
determined between 5 and 10 days.17 The laboratory refer-
ence strain, H37Rv, was used as the control for all the assays.
The GenoType MTBDRsl version 2.0 (Hain Lifesciences, 
Germany), a line probe assay, was used to screen 93 of 
the 117 phenotypically screened isolates according to the 
manufacturer’s instruction.18 The isolates used for this assay 
included all the MDR-TB (71) and RIF monoresistant (13) 
isolates and an additional nine INH monoresistant isolates. 
Mutation analysis of drug targets
The isolates with high MICs by the Etest method (i.e., ≥2 µg/
mL for STR, ≥1 µg/mL for AMK and ≥0.125 µg/mL for MOX) 
and resistant by the line probe assay were used for targeted DNA 
sequence analyses. In total, 26 isolates were sequenced includ-
ing 14 control isolates that were susceptible to all the drugs. 
DNA segments of the respective resistance conferring genes 
gyrA, gyrB, rrs, eis, tlyA, tap and whiB7 were amplified using 
polymerase chain reaction (PCR) for direct DNA sequencing. 
The PCR for gyrA, gyrB, tlyA and whiB7 contained 5 µL of 
10× buffer, 10 µL of Q-solution, 2.5 µL of 15 mM of MgCl
2, 
1 
µL of dNTPs, 21.2 µL of nuclease-free water, 2.5 µL each of 
forward and reverse primers, 0.3 µL of HotStar Taq polymerase 
and 5 µL of DNA. Cycling conditions were as follows: initial 
activation step at 95°C for 5 min and 35 cycles of denaturation 
at 96°C for 1 min, annealing for 1 min at primer-specific 
temperature Tm (Table 1), extension at 68°C for 1 min and 
final extension at 72°C for 10 min. The PCR mixtures for rrs, 
eis and tap genes contained 25 µL of fast cycling master mix, 
10 µL of Q-solution, 2.5 µL of each of the primers, 5 µL of 
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 nuclease-free water and 5 µL of DNA template. The cycling 
conditions included initial denaturation step at 95°C for 5 min 
and 40 cycles of denaturation at 96°C for 5 s, annealing for 5 s 
at primer-specific temperature Tm (Table 1), extension at 68°C 
for 48 s and final extension at 72°C for 1 min.
Data analysis
Fisher’s exact test and chi-squared test were carried out using 
Stata 14.3 to determine the differences between the patient 
categories (new TB cases and treatment failure cases) and 
the frequency of second-line drug-resistant isolates. Also, 
the correlation coefficient was determined between the year 
of isolation of the MTB isolates from the patients and the 
prevalence of anti-TB drug resistance. 
Drug resistance according to the line probe assay was 
indicated by the absence of wild-type band, presence of 
mutation band, or both. For interpretation of the results, only 
bands with intensities as strong as or stronger than that of 
the universal control band were considered.18
DNA reads obtained from sequencing were edited and 
cleaned to remove background noise. The cleaned sequences 
were screened for mutations by comparing with homologous 
sequences of Mycobacterium tuberculosis strain H37Rv 
downloaded from the Tuberculist database version 2.6 using 
the Staden package for DNA analysis.19,20 The results from 
this mutation analysis were compared with the identified 
mutations from the line probe assay. 
Results
Biographical data of study participants
Most of the participants were males: 83 (74.8%) males, 28 
(25.2%) females and six participants had no record of gender. 
The average age was 37 years, median age was 34 years and 
the range was between 13 and 79 years (Table 2). Major-
ity of the participants, 69 (59.0%), were newly diagnosed 
cases; TB patients with treatment failure were 47 (40.2%) 
and one relapse case was also included in the study. The 
Table 1 Primer sequences with the optimized annealing temperature for the targets
Gene Primer name Primer sequence Annealing 
Temperature (°C)
Amplicon size
gyrA F-gyr A 5′-cagcTacaTcgacTaTgcga-3′ 60 320
R-gyr A 5′-gggcTTcggTgTaccTcaT-3′
gyrB F-gyr B 5′-cgTaaggcacgagagTTggT-3′ 60 300
R-gyr A 5′-aTcTTgTggTagcgcagcTT-3′
rrs F-rrs 5′-TTcTaaaTaccTTTggcTcccT-3′ 60 1,680
R-rrs 5′-TggccaacTTTgTTgTcaTgca-3′
eis F-Rv2417c 5′-gcggTgcaTcacgTcgccga-3′ 61 1,660
R-eis-Rv2415c 5′-gcaacgcgaTccgcgagTgc-3′
tlyA F-tlyA 5′-gTggcacgacgTgcccgcgT-3′ 64 807
R-tlyA 5′-cTacgggcccTcgcTaaTcg-3′
tap F-Rv1259 5′-caggccggcccTaTgcagTg-3′ 61 1,847
R-Rv1257c 5′-cggTcTTgccggTagccgTc-3′
whiB7 F URT-whiB7 5′-gcTggTTcgcggTcggaccT-3′ 60 550
R whiB7 5′-cggggTaTcggcgaaccaca-3′
Abbreviations: F, forward; R, reverse.
Table 2 Characteristics of study participants
Variable (number of patients) Number (%)
age (108)
average age 
Minimum age
37 years
13 years
Maximum age 79 years
Median age 34 years
gender available (111)
Male 83 (74.8)
Female 28 (25.2)
Patient category (117)
new cases 69 (59.0)
Treatment failure 47 (40.2)
Relapse 1 (0.8)
Location (region) of patients (117)
greater accra 72 (61.5)
central 21 (17.9)
northern 9 (7.7)
Volta 7 (6.0)
Upper east 4 (3.4)
Brong/ahafo 2 (1.7)
Western 1 (0.9)
eastern 1 (0.9)
Year of isolation of isolates from  
patients (117)
2008 14 (12.0)
2010 16 (13.7)
2012 10 (8.5)
2013 14 (12.0)
2014 37 (31.6)
2015 26 (22.2)
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residential address of the study participants indicated they 
were from eight different administrative regions: 72 (61.5%) 
from Greater Accra region, 21 (17.9%) from Central region, 
nine (7.7%) from Northern region, seven (6.0%) from Volta 
region, four (3.4%) from Upper East region and two (1.7%) 
from Brong/Ahafo region. The participants also included 
one participant each from Eastern and Western region. The 
study participants were recruited between 2008 and 2015. 
Second-line anti-TB drug profiles
We determined the MIC values of 117 isolates for STR, AMK 
and MOX (Table 3). However, one isolate was eliminated 
from the analysis of the results since it had a result discrepant 
with another laboratory. 
The time for the Etest ellipse to become visible for the 
MIC determination was recorded for each isolate and 114 
(97.4%) of the isolates were read between 5 and 10 days. Out 
of the total isolates screened, 37 (31.9%) had MICs ≥2 µg/
mL for STR and 12 (10.3%) isolates presented with MICs ≥1 
µg/mL for AMK. Only one MDR isolate (Isolate ID: TB/Nm 
919) had an MIC value ≥0.125 µg/mL for MOX (MIC = 3µg/
mL); this isolate also had the highest MIC value for AMK (16 
µg/mL) and a very high MIC for STR (32 µg/mL) (Table 4).
Out of 69 isolates from new TB cases, eight (11.59%) 
were resistant to AMK, while four (8.51%) of the 47 treat-
ment failures were AMK resistant. However, there was no 
significant difference between these two patient categories 
(p = 0.759). Also, we identified no significant difference 
between the proportion of isolates resistant to STR among the 
new TB cases (31.88%) compared to the treatment failures 
(31.91%, p = 0.997). There was only one MOX-resistant 
isolate which was a treatment failure case. There was no 
significant difference between the patient categories for MOX 
resistance (p = 0.405).
There was also no correlation between the year of isola-
tion of the MTB isolates from the patients and the prevalence 
of anti-TB drug resistance (correlation coefficient, r = 0). 
We screened 93 (including all MDRs) of the 117 iso-
lates by GenoType MTBDRsl version 2.0. As summarized 
in Table 3, the isolate TB/Nm 919 was cross-resistant to 
AMK/kanamycin (KAN)/capreomycin (CAP) and also fluo-
roquinolone resistant. It had a mutation band MT 1, which 
corresponded to substitution A1401G in the rrs gene. Fur-
thermore, there was an absence of a wild-type band (WT 1) 
in the gyrA of this isolate that corresponded to the G88C 
single-nucleotide polymorphism (SNP), which is associated 
with resistance to fluoroquinolones. This XDR-TB isolate 
was cultured from the sputum of a 42-year-old fisherman T
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who had failed TB treatment. He died 2 years after he had 
reported to the hospital with persistent cough in January 
2013. The first drug susceptibility testing conducted showed 
he was resistant to ethambutol, STR, RIF and INH.
There was no mutation or missing wild-type band in the 
eis and gyrB genes among all the isolates screened using the 
GenoType MTBDRsl version 2.0. 
Mutations in aminoglycoside and 
fluoroquinolone resistance associated 
target genes
To identify the mutations associated with resistance to fluoro-
quinolones and aminoglycosides, 26 isolates were tested. Of 
the 26, 12 were isolates with high MICs for AMK and MOX 
or resistant by the line probe assay, GenoType MTBDRsl 
version 2.0. The other 14 were susceptible to all the second-
line anti-TB drugs. A non-synonymous mutation, G263T that 
translates as G88C, was identified in the gyrA gene of isolate 
TB/Nm 919. This same isolate had the SNPs A1401G and 
A514C in the rrs gene (Table 4). We also detected a polymor-
phism N236K in tlyA gene in a drug-susceptible isolate. We 
did not find any mutation in gyrB, tap, eis and whiB7 genes.
Discussion
This study sought to determine the prevalence of second-
line anti-TB drug resistance in Ghana. Prior to this study, 
only a few drug resistance surveys had been carried out on 
new TB cases and treatment failure cases in Ghana.17,21,22 
The high STR resistance levels observed in this study is 
even lower than that achieved by Forson et al and Kato et al 
that recorded 79% and 81%, respectively, among treatment 
failures in Ghana.22,23 The high level of resistance to STR 
strengthens the WHO’s recommendation not to use STR for 
the treatment of MDR-TB cases.24 The high prevalence of 
STR resistance in Ghana can be attributed to its previous use 
as first-line anti-TB drug and also for treating other ailments 
and in veterinary medicine.21,25,26
The first second-line anti-TB drug testing in Ghana by 
Kato et al was carried out on 5 MDR-TB and 19 monore-
sistant isolates from four new cases and 17 treated cases. 
They did not record any resistance to AMK and ofloxacin.22 
However, a later study conducted between 2009 and 2013 in 
eight West African countries by the West African Network 
of Excellence for Tuberculosis, AIDS and Malaria (WANE-
TAM), identified resistance to KAN, CAP and ofloxacin for 
the first time in Ghana. They also observed a higher preva-
lence of MDR-TB in new and retreatment cases (6% and 
35%, respectively) compared to the WHO estimates of 2% 
for new cases and 17% for retreatment cases.27 The study by 
Kato et al was actually carried out between 2008 and 2009 
and the reporting of resistance by the WANETAM indicates 
the emergence of resistance.22,27 The resistance reported by 
this study also suggests the circulation of resistant strains 
in the country. 
Mutations associated with resistance to fluoroquinolones 
and aminoglycosides was analyzed by GenoType MTBDRsl 
version 2.0 and drug target gene sequencing. The G88C 
mutation observed in the gyrA gene by targeted sequencing 
corresponded with the missing of gyrA wild-type band of 
the GenoType MTBDRsl version 2.0 assay. This mutation 
has been shown to be associated with resistance to fluoro-
quinolones.28,29 Although a review by Avalos et al observed 
geographic differences in the gyrA mutations across the globe, 
the use of GenoType MTBDRsl version 2.0 in Ghana was 
useful in the detection of this resistance-associated mutation.30
The target gene sequencing showed three SNPs (A1401G 
and A514C in rrs and N236K in tlyA) that are associated with 
aminoglycoside resistance. The isolate that had rrs MUT 1 
band of the GenoType MTBDRsl version 2.0 assay also had 
a corresponding rrs mutation (A1401G). This is a common 
mutation reported in several studies to be associated with 
resistance to AMK, KAN and CAP.31–34 The tlyA missense 
mutation observed is an infrequent mutation that is associated 
with CAP resistance;35,36 however, the respective isolates were 
not tested phenotypically against CAP. There was no mutation 
in the eis gene by both molecular methods. The GenoType 
MTBDRsl version 2.0 included the eis gene probe which 
was missing in the GenoType MTBDRsl version 1.0 and a 
study by Tagliani et al showed that the inclusion of the probe 
for the eis promoter gene in the version 2.0 had increased 
the sensitivity for the detection of resistance to the amino-
glycosides. However, this study did not detect any mutation 
band or missing wild-type band in the eis promoter region.37 
Our analysis, to the best of our knowledge, identified one 
XDR-TB isolate for the first time in Ghana. The progressive 
identification of resistant isolates in Ghana if not controlled 
will pose a great challenge to the control of TB in Ghana. 
This calls for immediate action, including continuous surveil-
lance, patient counseling/support to improve adherence to 
treatment and drug supply management to prevent the spread 
of XDR-TB in Ghana. The findings have been reported to 
the NTP to take the necessary actions. The contacts of the 
presumed XDR-TB patient have been screened for TB and 
are being monitored. 
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
80
.2
29
.2
44
 o
n 
21
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
244
Osei-Wusu et al
Conclusion
We thus recommend the inclusion of routine testing for 
second-line drug resistance among RIF and MDR-TB cases 
in our diagnostic algorithm. 
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